← Leaderboards
Fenghuang Zhan
University Of Utah
$4,770,820
Attributed
$4,770,820
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $802.5K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,770,820 · 4
VA$0 · 1
By mechanism
R01$3,537,452 · 2
U54$879,261 · 1
R21$354,107 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- Bradley R Cairns$10,773,002
- Pamela B Cassidy$1,236,708
- Jun Yang$6,508,633
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelSignal PathwayCellsMultiple MyelomaProteinsMalignant NeoplasmsNeoplastic CellSamplingCell GrowthGenesDrug ResistanceResistancePharmaceutical PreparationsIn VitroGeneticIn VivoApoptosisBiologySignal TransductionMediatingCell SurvivalRelapseHigh RiskDisease Progression
Grant awards (19)
Prevention of MGUS Progression to MM by Modulating the Bone Marrow Microenvironment$327,231
U54 · FY2025 · CA · contact PI
Characterize Drug Resistance in Multiple Myeloma$0
I01 · FY2025 · VA · contact PI
Novel NEK2 signaling pathways in myeloma progression$330,316
R01 · FY2024 · CA · contact PI
Prevention of MGUS Progression to MM by Modulating the Bone Marrow Microenvironment$261,630
U54 · FY2024 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression$340,746
R01 · FY2023 · CA · contact PI
Prevention of MGUS Progression to MM by Modulating the Bone Marrow Microenvironment$290,400
U54 · FY2023 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression$171,306
R01 · FY2023 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression$340,746
R01 · FY2022 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression - Bauer Diversity Supplement$161,511
R01 · FY2022 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression$347,700
R01 · FY2021 · CA · contact PI
Novel NEK2 signaling pathways in myeloma progression$347,510
R01 · FY2020 · CA · contact PI
NEK2 Over-expression Causes Drug Resistance in Myeloma$294,808
R01 · FY2014 · CA · contact PI
NEK2 Over-expression Causes Drug Resistance in Myeloma$285,690
R01 · FY2013 · CA · contact PI
NEK2 Over-expression Causes Drug Resistance in Myeloma$303,925
R01 · FY2012 · CA · contact PI
NEK2 Over-expression Causes Drug Resistance in Myeloma$300,906
R01 · FY2011 · CA · contact PI
Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell$86,384
R21 · FY2011 · CA · contact PI
Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell$71,320
R21 · FY2011 · CA · contact PI
NEK2 Over-expression Causes Drug Resistance in Myeloma$312,288
R01 · FY2010 · CA · contact PI
Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell$196,403
R21 · FY2010 · CA · contact PI